Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 26 Nov 2021 Disposals of own shares Read More 19 Nov 2021 Disposals of own shares Read More 19 Nov 2021 Positive Top-Line Results from BIMZELX®▼(bimekizumab) Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms Read More 15 Nov 2021 Disposals of own shares Read More 5 Nov 2021 Disposals of own shares Read More 29 Oct 2021 Disposals of own shares Read More Pagination First page Previous page Previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
